



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), May 29, 2017

Pursuant to article 228 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October and to article 17 of Regulation (EU) n°596/2014 on market abuse, Pharma Mar, S.A. (“**Pharma Mar**” or the “**Company**”) hereby discloses the following **REGULATORY ANNOUNCEMENT**:

Pharma Mar, S.A. (“**Pharma Mar**” or the “**Company**”) informs that its subsidiary Sylentis, S.A.U. has initiated the first Phase III study, HELIX, with its investigational drug SYL1001 for the treatment of dry eye syndrome. It is also reported that tomorrow May, 30 at 13:00 hours it is planned to hold a press conference at NH Collection Madrid Abascal hotel in which will be analyzed the social incidence of dry eye syndrome in Spain and in the world, its economic impact on the market and the business project of Sylentis, among others, with the presence, among others, of Mr. José María Fernández (Chairman of Pharma Mar) and Ms. Ana Isabel Jiménez (Chief Operating Officer and R&D Director).